Philippines vs Thailand: Statin use vs. average non-HDL cholesterol levels
Philippines
4
in 2018
Thailand
4
in 2018
Philippines rank
2nd
Thailand rank
2nd
Statin use vs. average non-HDL cholesterol levels over time
- Philippines
- Thailand
How they compare
Philippines currently reports 4 against 4 in Thailand, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Philippines ahead.
Philippines ranks 2nd and Thailand ranks 2nd of 191 countries.
Across the 4 decades both report, Philippines averaged higher in 1 and Thailand in 3.
Head to head by decade
| Decade | Philippines | Thailand | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.45 | 3.44 | 0.01 | Philippines |
| 1990s | 3.51 | 3.7 | 0.19 | Thailand |
| 2000s | 3.65 | 3.88 | 0.23 | Thailand |
| 2010s | 3.9 | 4 | 0.1 | Thailand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Philippines or Thailand?
- Philippines, at 4 against 4 in Thailand as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Philippines and Thailand?
- 0, with Philippines ahead.
- How many years of comparable data are there for Philippines and Thailand?
- 39 years are reported by both, from 1980 to 2018.
- How do Philippines and Thailand rank globally for statin use vs. average non-hdl cholesterol levels?
- Philippines ranks 2nd and Thailand ranks 2nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.